Keyphrases
Acute Lymphoblastic Leukemia
25%
Alloantibody
12%
Autologous Stem Cells
12%
Bone Marrow
44%
Cell-free DNA (cfDNA)
34%
Cell-free RNA
12%
Childhood Cancer
12%
Circulating Tumor DNA (ctDNA)
15%
Copy number Aberrations
12%
Copy number Variation
15%
Diagnostic Biomarker
12%
Disease Diagnosis
12%
Disseminated Infection
12%
DNA Markers
25%
Droplet Digital PCR (ddPCR)
23%
Essential Medicines
12%
Europe
12%
Germ Cells
12%
Grafting from
12%
High-risk Neuroblastoma
13%
KMT2A
25%
Leukemia
12%
Lineage Switch
12%
Liquid Biopsy
42%
Minimal Residual Disease
87%
Molecular Detection
12%
Molecular Response
12%
Monolayer Integrity
12%
Multiplex RT-PCR
12%
Neuroblastoma
91%
Pediatric Patients
15%
Pediatric Rhabdomyosarcoma
12%
Pediatric Tumors
26%
PHOX2B
15%
Prognostic Biomarker
12%
Prognostic Value
12%
Quantitative PCR
36%
RASSF1A
37%
Regulatory Genes
12%
Rhabdomyosarcoma
25%
Risk Stratification
14%
RNA Markers
19%
Sensitive Detection
15%
Specific Detectivity
12%
Specific Marker
14%
Stem Cell Grafts
12%
Targeted Locus Amplification
12%
Technical Potential
12%
Tumor
27%
Working Diagnosis
31%
Medicine and Dentistry
Acute Lymphoblastic Leukemia
31%
Acute Myeloid Leukemia
6%
Adenosine Triphosphatase
6%
Biological Marker
12%
Cell-Free DNA
42%
CHRNA3
11%
Circulating Tumor DNA
12%
Deacetylation
6%
Diagnosis
18%
Disease
28%
Disseminated Disease
12%
DNA Marker
12%
Droplet Digital Polymerase Chain Reaction
27%
Event Free Survival
10%
Fusion Gene
12%
Ganglioneuroblastoma
100%
Gene Expression
8%
Gene Fusion
6%
Germ Cell
12%
Helicase
6%
Immunotherapy
6%
Leukemia
12%
Liquid Biopsy
45%
Messenger RNA
36%
Metastatic Carcinoma
14%
Minimal Residual Disease
76%
Neoplasm
48%
Overall Survival
7%
Patient with Neuroblastoma
21%
Pediatric Cancer
18%
Pediatrics
39%
Pediatrics Patient
16%
Precursor
6%
Primary Tumor
11%
Prognostic Factor
7%
Proportional Hazards Model
6%
Quantitative Reverse Transcription Polymerase Chain Reaction
14%
Real-Time Polymerase Chain Reaction
27%
Reduced Representation Bisulfite Sequencing
6%
Regulator Gene
12%
Rhabdomyosarcoma
34%
Risk Stratification
14%
RNA Directed DNA Polymerase
8%
Sensitive Detection
14%
Size-Exclusion Chromatography
8%
Solid Malignant Neoplasm
25%
Stem Cell
12%
Tumor Marker
6%
Whole Genome Sequencing
6%
Wilms' Tumor
8%